为研究基因治疗在造血功能损伤后恢复中的应用,本课题以携带小鼠IL-3基因的复制缺陷型重组腺病毒载体转染骨髓基质细胞,对大剂量化疗后的小鼠进行脾内移植观察造血功能的恢复情况.结果表明,缺陷型腺病毒载体能有效地转染小鼠原代骨髓基质细胞,转染效率在80%以上(MOI=10);基因修饰的骨髓基质细胞体外分泌IL-3的水平可达110U/ml/10~6细胞/24小时;在大剂量环磷酰胺治疗后脾内移植IL-3基因修饰的基质细胞能有效地升高实验小鼠外周血白细胞总数;病理检测发现IL-3基因修饰的基质细胞治疗组小鼠脾脏和骨髓中细胞增生较其它组明显活跃;经IL-3基因修饰的基质细胞治疗组小鼠脾淋巴细胞对ConA反应明显增强.结果提示IL-3基因修饰的骨髓基质细胞体内移植对大剂量化疗后机体造血与免疫功能的恢复都有较好的促进作用.

A main complication of chemotherapy in cancer patients is hematopoiesis suppression. Microenviroment transplantation using bone marrow stromal cells (BMSCs) has been demonstrated to be a potent method in recovery of hematopoiesis in animal models. Based on hematopoiesis-supportive ability of BMSCs and high potency of IL-3 in hematopoiesis stimulation, BMSCs were studied as a cellular delivery system for IL-3 gene transfection to promote hematopoiesis recovery of mice after high dose chemotherapy. BMSCs were transfected with recombinant adenovirous containing murine IL-3 gene(MOI = 10), the level of mIL-3 secreted by gene-modified BMSCs was 110U/ml/10~6 cells/ 24h in vitro. The mice were injected with high dose cyclophosphamide(200mg/kg) i.p. and after 24 hours the IL-3 gene-modified BMSCs(2 x 10~6/mouse) were transplanted intrasplenically. White blood cell counts in peripheral blood of mice received intrasplenic injection of IL-3-BMSCs were kept at a high level within two weeks after chemotherapy. The pathological sections of spleens and bone marrow showed significant recovery of hematopoiesis, compared with that of mice received chemotherapy only. The data indicated the feasibility of IL-3 gene-modified BMSCs transplantation in the acceleration of hematopoiesis recovery after chemotherapy.

全军九五重点基金(96Z032)资助